Active Pharmaceutical Ingredients
Levocetirizine Dihydrochloride Sustained Release (SR) Pellets are formulated to offer prolonged antihistaminic action by gradually releasing the active ingredient over an extended period. These pellets are designed for once-daily dosing, improving patient compliance and minimizing sedation commonly associated with immediate-release antihistamines. Leveraging advanced coating technologies, the SR pellets ensure consistent plasma levels and are ideal for oral capsule or sachet formulations.
| Component | Function |
|---|---|
| Levocetirizine Dihydrochloride | Active Pharmaceutical Ingredient (API) |
| Sugar Spheres / MCC Pellets | Inert core / Neutral starter spheres |
| HPMC / PVP | Binder / Layering polymer |
| Ethyl Cellulose / Eudragit RS/RL | Sustained-release polymer for controlled release |
| Triethyl Citrate / PEG 6000 | Plasticizer to enhance film flexibility |
| Talc / Colloidal Silicon Dioxide | Anti-adherent / Glidant |
| Purified Water | Solvent (removed during processing) |
Salius Pharma offers Levocetirizine Di HCl SR Pellets manufactured in USFDA-approved, WHO-GMP, and ISO-certified facilities in India, ensuring global quality standards and regulatory compliance. Our pellets are developed using optimized sustained-release coating technologies to ensure controlled drug delivery and consistent plasma levels. Available in customized strengths and pellet sizes, they are ideal for capsule or sachet formulations. With proven export capabilities across Africa, Southeast Asia, CIS, and LATAM, Salius provides end-to-end support—from formulation development and documentation (CTD, CoA, MSDS) to reliable global logistics.
We ensure prompt and reliable shipping worldwide. Delivery times may vary depending on destination, order volume, and regulatory requirements.
Looking to source Levocetirizine Di HCl SR Pellets or other high-quality pharmaceutical pellet formulations?
Whether you need Active Pharmaceutical Ingredients (APIs), excipients, or regulatory support, our team is ready to provide reliable, compliant, and cost-effective solutions tailored to your market needs.
The contents of this page and any attachments are intended solely for the designated recipient(s) and may contain confidential and/or privileged information protected by law.
Any patented products are excluded from our offerings in regions where such patents are currently in force.
Sustained release pellets provide once-daily dosing, reduced sedation, and consistent antihistaminic activity over 12–24 hours, avoiding plasma level fluctuations seen with immediate-release formulations.
Yes, release kinetics can be customized using polymer blends such as Ethyl Cellulose or Eudragit RS/RL to achieve 12-hour, 18-hour, or 24-hour controlled release profiles.
Pellets are supplied in export-grade, moisture-protected packaging with complete documentation including CoA, MSDS, and stability data to support global regulatory compliance.